[go: up one dir, main page]

ES2034891B1 - Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas. - Google Patents

Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.

Info

Publication number
ES2034891B1
ES2034891B1 ES9101859A ES9101859A ES2034891B1 ES 2034891 B1 ES2034891 B1 ES 2034891B1 ES 9101859 A ES9101859 A ES 9101859A ES 9101859 A ES9101859 A ES 9101859A ES 2034891 B1 ES2034891 B1 ES 2034891B1
Authority
ES
Spain
Prior art keywords
nanocapsules
nanoparticles
chemically
preparing
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES9101859A
Other languages
English (en)
Other versions
ES2034891A1 (es
Inventor
Valdivia F Javier Galan
Mas Jose Alberto Vallet
Michael V W Bergamini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES9101859A priority Critical patent/ES2034891B1/es
Priority to DE4128910A priority patent/DE4128910A1/de
Priority to AT92202434T priority patent/ATE150642T1/de
Priority to EP92202434A priority patent/EP0529711B1/en
Priority to JP4212681A priority patent/JP2542149B2/ja
Publication of ES2034891A1 publication Critical patent/ES2034891A1/es
Application granted granted Critical
Publication of ES2034891B1 publication Critical patent/ES2034891B1/es
Priority to US08/309,797 priority patent/US5705196A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/778Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783Organic host/matrix, e.g. lipid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/832Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
    • Y10S977/835Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/832Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
    • Y10S977/835Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial
    • Y10S977/836Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial having biological reactive capability
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/90Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO DE ELABORACION EN CONTINUO DE SISTEMAS COLOIDALES DISPERSOS, EN FORMA DE NANOCAPSULAS O NANOPARTICULAS. COMPRENDE: (1) PREPARAR UNA FASE ACUOSA CONTENIENDO AGENTES TENSOACTIVOS, SUSPENSORES Y, OPCIONALMENTE, UNA SUSTANCIA QUIMICA O BIOLOGICAMENTE ACTIVA; (2) PREPARAR UNA FASE ORGANICA CONTENIENDO UN POLIMERO O MONOMERO BIOCMPATIBLE Y, OPCIONALMENTE, UN LIPIDO O UNA SUSTANCIA QUIMICA O BIOLOGICAMENTE ACTIVA; (3) MEZCLAR AMBAS FASES EN FORMA CONTINUA EN UNA RELACION DE FASES Y VOLUMEN MEDIO CONSTANTE, RETIRANDO CONTINUAMENTE A SUSPENSION COLOIDAL RECIEN FORMADA; (4) ELIMINAR DE FORMA CONTINUA EL DISOLVENTE DE LA SUSPENSION COLOIDAL; Y (5) ELIMINAR POR COMPLETO EL DISOLVENTE ORGANICO Y PARTE O TODA EL AGUA PARA OBTENER LA CONCENTRACION DESEADA DE NANOESFERAS O EL PRODUCTO SECO. APLICACION EN BIOMEDICINA, FARMACIA, MEDICINA, COSMETICA, INDUSTRIA QUIMICA, AGRICULTURA Y VETERINARIA, ETC.
ES9101859A 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas. Expired - Lifetime ES2034891B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES9101859A ES2034891B1 (es) 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
DE4128910A DE4128910A1 (de) 1991-08-08 1991-08-30 Verfahren zur kontinuierlichen herstellung feinverteilter kolloidsysteme in form von nanokapseln oder nanopartikeln
AT92202434T ATE150642T1 (de) 1991-08-08 1992-08-05 Verfahren zur kontinuierlichen herstellung von dispersen kolloide-systemen in form von nanokapseln oder nanopartikeln
EP92202434A EP0529711B1 (en) 1991-08-08 1992-08-05 Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles
JP4212681A JP2542149B2 (ja) 1991-08-08 1992-08-10 ナノカプセルあるいはナノ粒子の分散コロイダル系の連続製造方法
US08/309,797 US5705196A (en) 1991-08-08 1994-09-21 Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9101859A ES2034891B1 (es) 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.

Publications (2)

Publication Number Publication Date
ES2034891A1 ES2034891A1 (es) 1993-04-01
ES2034891B1 true ES2034891B1 (es) 1993-12-16

Family

ID=8273277

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9101859A Expired - Lifetime ES2034891B1 (es) 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.

Country Status (6)

Country Link
US (1) US5705196A (es)
EP (1) EP0529711B1 (es)
JP (1) JP2542149B2 (es)
AT (1) ATE150642T1 (es)
DE (1) DE4128910A1 (es)
ES (1) ES2034891B1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2078190B1 (es) * 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
DE69526787T2 (de) * 1995-07-05 2002-12-05 European Community, Luxemburg/Luxembourg Biokompatibele und biodegradierbare Nanokapseln zur Absorption und Verabreichung von proteinischen Arzneimitteln
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
JP3650582B2 (ja) 1998-11-30 2005-05-18 ナノスフェアー インコーポレイテッド ポリマー−ナノ粒子ハイブリッド粒子
WO2000035577A1 (de) * 1998-12-11 2000-06-22 Henkel Kommanditgesellschaft Auf Aktien Verfahren zur herstellung von nanopartikeldispersionen
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
FR2805761B1 (fr) 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
KR100681213B1 (ko) * 2002-09-11 2007-02-09 다나베 세이야꾸 가부시키가이샤 마이크로스피어의 제조 방법 및 제조 장치
US7112620B2 (en) * 2002-10-18 2006-09-26 Albright Robert L Hemocompatible polymer systems & related methods
JP4341238B2 (ja) * 2002-12-16 2009-10-07 日油株式会社 繊維加工方法および繊維
WO2005016976A2 (en) * 2003-05-27 2005-02-24 Albright Robert L Hemocompatible polymer systems and related methods
US20060151899A1 (en) * 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
US7714015B2 (en) * 2003-08-07 2010-05-11 Lil Brat Pharmaceuticals Of Marlette, Mi Method and composition for treating sunburned skin
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
AU2020299588B2 (en) 2019-07-01 2022-03-03 Oakwood Laboratories, Llc System and method for making microspheres and emulsions
US20220361552A1 (en) * 2019-12-10 2022-11-17 Tyler White Particles Containing a Lipid Matrix Core and Active Ingredient

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
CH594444A5 (es) * 1972-12-04 1978-01-13 Gerd Birrenbach
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4489055A (en) * 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
EP0007895B1 (fr) * 1978-07-19 1983-06-22 Patrick Couvreur Nanoparticules biodégradables, compositions pharmaceutiques les contenant et procédé pour leur préparation
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
DE2940676A1 (de) * 1979-10-08 1981-04-16 Krupp Polysius Ag, 4720 Beckum Anlage zur waermebehandlung von feinkoernigem gut
FR2515960A1 (fr) * 1981-11-06 1983-05-13 Alkhouri Fallouh Nazir Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application
US4798786A (en) * 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
CH653553A5 (en) * 1982-11-01 1986-01-15 Sandoz Ag Microencapsulation process
US4670250A (en) * 1983-10-21 1987-06-02 Bend Research, Inc. Durable controlled release microcapsules
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JPH02242826A (ja) * 1988-11-25 1990-09-27 Mitsui Petrochem Ind Ltd 塩素化エチレン・α‐オレフィン共重合体ラテックスの製造方法
US4990431A (en) * 1989-01-17 1991-02-05 Eastman Kodak Company Methods of forming stable dispersions of photographic materials
FR2660193B1 (fr) * 1990-04-03 1994-11-04 Philippe Maincent Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules.
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.

Also Published As

Publication number Publication date
ES2034891A1 (es) 1993-04-01
EP0529711B1 (en) 1997-03-26
JP2542149B2 (ja) 1996-10-09
JPH0657005A (ja) 1994-03-01
ATE150642T1 (de) 1997-04-15
DE4128910A1 (de) 1993-02-11
EP0529711A1 (en) 1993-03-03
US5705196A (en) 1998-01-06

Similar Documents

Publication Publication Date Title
ES2034891B1 (es) Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
Dynarowicz-Łątka et al. Molecular interaction in mixed monolayers at the air/water interface
Alivisatos et al. Organization of'nanocrystal molecules' using DNA
Brick et al. Formation of colloidal dispersions of organic materials in aqueous media by solvent shifting
Sriamornsak et al. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: effect of some additives, hardening agent or coating on release behavior of metronidazole
DE69426568D1 (de) Verfahren zur umhüllung von nanopartikeln oder -tröpfchen
FR2755136B1 (fr) Procede de preparation de nanoparticules de methylidene malonate, nanoparticules contenant eventuellement une ou plusieurs molecules biologiquement actives et compositions pharmaceutiques les contenant
JPH0940545A (ja) アスコルビン酸を含有する安定組成物
FR2760641B1 (fr) Emulsion huile-dans-eau stable, son procede de fabrication et son utilisation dans les domaines cosmetique et dermatologique
WO2001051196A1 (en) Templating of solid particles by polymer multilayers
GR3022703T3 (en) Protein nanomatrixes and method of production
EP1129683A4 (en) HYALURONIC ACID, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL MATERIALS CONTAINING THIS
ATE84710T1 (de) Verfahren zur herstellung von kolloidalen dispergierbaren proteinsystemen, wie nanopartikeln.
BR0005141A (pt) Emulsão cosmetica ou dematológica sem emulsionante, composição cosmética ou dermatológica destinada a fotoproteção da pele e/ou dos cabelos, utilização de emulsão e utilização de um polìmero associativo
Jagtap et al. Nanosponges: a novel trend for targeted drug delivery
FR2661414B1 (fr) Produit a base de keratines modifiees, son procede de preparation et les applications notamment en medecine humaine ou veterinaire.
Loftsson et al. The effects of cyclodextrins on transdermal delivery of drugs
Loftsson et al. The influence of 2-hydroxypropyl-β-cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone
Rossi et al. Toward an understanding of the thermosensitive behaviour of pH-responsive hydrogels based on cyclodextrins
Helttunen et al. Solid lipid nanoparticles from amphiphilic calixpyrroles
GB1389238A (en) Process for encapsulating or coating finely divided materials by spray-drying-induced polymerisation
Li et al. Organic-inorganic hybrid based on co-assembly of polyoxometalate and dopamine for synthesis of nanostructured Ag
Joo et al. Colloidal stability and in vitro permeation study of poly (ɛ-caprolactone) nanocapsules containing hinokitiol
Mironov et al. Enzymatic degradation of the polymer capsules with a hydrophobic core in the presence of Langmuir lipid monolayer as a model of the cellular membrane
Egea et al. Interaction of amikacin loaded nanoparticles with phosphatidylcholine monolayers as membrane models